 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
44 News |  |
- || Lastacaft (alcaftadine) / J&J, AbbVie, olopatadine / Generic mfg.
Retrospective data, Review, Journal: Comparative assessment of alcaftadine and olopatadine for allergic conjunctivitis: a meta-analysis. (Pubmed Central) - Jan 29, 2025
These two groups had similar incidence of adverse events (OR = 0.61; 95% CI = 0.34 to 1.09; p = 0.10). Alcaftadine had better capability to treat allergic conjunctivitis compared to olopatadine.
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Lastacaft (alcaftadine) / J&J, AbbVie
Journal: Cutaneous Calcium/Calmodulin-Dependent Protein Kinase II-?-Positive Sympathetic Nerves Secreting Norepinephrine Dictate Psoriasis. (Pubmed Central) - Mar 28, 2024
inhibitor, relieves imiquimod-induced psoriasis-like manifestations in mice. This study reveals the mechanisms of sympathetic-nervous-system regulation of ??T-cell interleukin-17 secretion, and provides insight into neuropsychiatric factors dictating psoriasis pathogenesis and new potential targets for clinical psoriasis treatment.
- | Lastacaft (alcaftadine) / J&J, AbbVie
Journal: Practice patterns and opinions in the treatment of allergic eye disease: A survey among Indian ophthalmologists. (Pubmed Central) - Jan 3, 2023
Respondents were asked about the newer molecule (alcaftadine) and reservations regarding systemic immuno-suppressants and ordering allergy tests in their practice...The signs and symptoms can vary from subtle, innocuous forms to devastating variants affecting vision and day-to-day work. This survey aims to elicit responses from clinicians spreading across different geographical areas and compares responses based on experience in practice.
- | Lastacaft (alcaftadine) / J&J, AbbVie
Journal: In brief: OTC alcaftadine (Lastacaft Once Daily Relief) for allergic conjunctivitis. (Pubmed Central) - May 18, 2022
This survey aims to elicit responses from clinicians spreading across different geographical areas and compares responses based on experience in practice. No abstract available
- ||| Lastacaft (alcaftadine) / J&J, AbbVie
#CHCNewsflash: #Lastacaft alcaftadine ophthalmic 0.25% solution (@allerganeye #Allergan / @abbvie #AbbVie) is now available without a prescription online and in retail stores for individuals aged 2+ years with ocular allergies. (Twitter) - Mar 18, 2022
- || Lastacaft (alcaftadine) / J&J, AbbVie
$ABBV Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours https://t.co/55tqBpI0oM (Twitter) - Mar 15, 2022
- | Lastacaft (alcaftadine) / J&J, AbbVie
Journal: Development of allergic conjunctivitis induced by Acanthamoeba excretory-secretory protein and the effect of resolvin D1 on treatment. (Pubmed Central) - Mar 4, 2022
All findings were significantly decreased upon treatment with RvD1 and the antiallergic agents. Acanthamoeba could be used to establish an animal model of AC, which could be effectively treated with RvD1 or topical antiallergic agents.
- ||| Lastacaft (alcaftadine) / J&J, AbbVie
Clinical, P3 data, Journal: Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study. (Pubmed Central) - Feb 26, 2022
Acanthamoeba could be used to establish an animal model of AC, which could be effectively treated with RvD1 or topical antiallergic agents. Once-daily Alcaftadine 0.25% is safe and effective in preventing signs and symptoms of Japanese cedar-pollen allergic conjunctivitis.
- | Lastacaft (alcaftadine) / J&J, AbbVie
Journal: Stability-indicating UPLC, TLC-densitometric and UV-spectrophotometric methods for alcaftadine determination. (Pubmed Central) - Jul 28, 2021
The proposed methods were successful for quantitation of alcaftadine in ophthalmic solution and in plasma samples. The obtained results were in accordance with those obtained by previously reported methods.
- || Lastacaft (alcaftadine) / J&J, AbbVie, Allelock (olopatadine) / Daewoong Pharma, Kyowa Hakko Kirin, Alcon
Clinical, Journal: Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. (Pubmed Central) - May 28, 2021
All three topical ophthalmic medications used in the study are safe and effective in the treatment of allergic conjunctivitis. However, Bepotastine and Alcaftadine appear to outweigh Olopatadine in resolving the symptoms of allergic conjunctivitis.
- | Veramyst (fluticasone furoate nasal spray) / GSK, Xolair (omalizumab) / Roche, Novartis
Journal: Drugs for allergic rhinitis and allergic conjunctivitis. (Pubmed Central) - Apr 20, 2021
However, Bepotastine and Alcaftadine appear to outweigh Olopatadine in resolving the symptoms of allergic conjunctivitis. No abstract available
- || Lastacaft (alcaftadine) / Allergan, J&J
Não acredito que paguei R$ 57,00 em 3ml de lastacaft @Allergan (Twitter) - Apr 12, 2020
- | Journal: Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents. (Pubmed Central) - Mar 10, 2020
Alcaftadine seems to have less side effects and better therapeutic effects than the other two anti-allergic agents tested. It may be more beneficial to use less toxic agents for patients with ocular surface risk factors or presumed symptoms of toxicity.
- || Clinical, Journal: Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis. (Pubmed Central) - Feb 7, 2020
Few cases with limbal or palpebral papillae reported symptomatic relief after use of medication, but the resolution of these signs was not noted in all three groups. We concluded similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis.
- || Lastacaft (alcaftadine) / Allergan, J&J, Allelock (olopatadine) / Daewoong Pharma, Kyowa Hakko Kirin, Alcon
Clinical, Journal: Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study. (Pubmed Central) - Jan 2, 2020
We concluded similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis. Alcaftadine 0.25% is effective in preventing signs and symptoms of Japanese cedar pollen-induced allergic conjunctivitis.
- | Lastacaft (alcaftadine) / Allergan, J&J
Clinical, Journal: Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report. (Pubmed Central) - Aug 15, 2019
Alcaftadine 0.25% is effective in preventing signs and symptoms of Japanese cedar pollen-induced allergic conjunctivitis. Although there have been no previous reports of alcaftadine 0.25%-associated ACD, it should be suspected in patients with swelling and erythematous change of both eyes after using alcaftadine 0.25%.
- | Alesion (epinastine) / Boehringer Ingelheim
Journal: Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends. (Pubmed Central) - Jun 5, 2019
The topical dual-action agents are the most effective agents treating signs and symptoms of mild forms of AC. There is superiority to the high-concentration olopatadine drug over other agents on ocular itch, with prolonged effect when used once-daily.
- ||||||| Lastacaft (alcaftadine) / J&J, AbbVie
Trial completion, Phase classification: Safety and Efficacy of Lastacaft (clinicaltrials.gov) - Apr 3, 2018
P, N=3423, Completed, Sponsor: Allergan
There is superiority to the high-concentration olopatadine drug over other agents on ocular itch, with prolonged effect when used once-daily. Recruiting --> Completed | Phase classification: PN/A --> P
- || Lastacaft (alcaftadine) / J&J, AbbVie
Trial completion date, Trial primary completion date: Safety and Efficacy of Lastacaft (clinicaltrials.gov) - Mar 8, 2018
P=N/A, N=3000, Recruiting, Sponsor: Allergan
Recruiting --> Completed | Phase classification: PN/A --> P Trial completion date: Feb 2018 --> Mar 2018 | Trial primary completion date: Feb 2018 --> Mar 2018
- | Lastacaft (alcaftadine) / J&J, AbbVie, Bepreve (bepotastine besilate ophthalmic solution) / Bausch Health
Trial completion: A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=25, Completed, Sponsor: Cunningham, Derek N., O.D., P.A.
Trial completion date: Feb 2018 --> Mar 2018 | Trial primary completion date: Feb 2018 --> Mar 2018 Recruiting --> Completed
- ||| Lastacaft (alcaftadine) / J&J, AbbVie
Enrollment open: Safety and Efficacy of Lastacaft (clinicaltrials.gov) - Dec 11, 2015
P=N/A, N=3000, Recruiting, Sponsor: Allergan
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Lastacaft (alcaftadine) / J&J, AbbVie
Trial completion, Enrollment change: A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy (clinicaltrials.gov) - Oct 22, 2015
P4, N=25, Completed, Sponsor: ORA, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=12 --> 25
- ||| Lastacaft (alcaftadine) / J&J, AbbVie
New trial: Safety and Efficacy of Lastacaft (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=3000, Not yet recruiting, Sponsor: Allergan
- | Lastacaft (alcaftadine) / J&J, AbbVie
New P4 trial: A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy (clinicaltrials.gov) - Dec 6, 2014
P4, N=12, Active, not recruiting, Sponsor: ORA, Inc.
- | Lastacaft (alcaftadine) / J&J, AbbVie
Enrollment open: (OAT-PIT): Ocular Allergy Treatment Practical Impact Trial (clinicaltrials.gov) - May 28, 2013
P4, N=50, Recruiting, Sponsor: Starx Research Center, LLC
Active, not recruiting --> Completed | N=12 --> 25 Not yet recruiting --> Recruiting
- | Lastacaft (alcaftadine) / J&J, AbbVie
New P4 trial: (OAT-PIT): Ocular Allergy Treatment Practical Impact Trial (clinicaltrials.gov) - Mar 7, 2013
P4, N=50, Recruiting, Sponsor: Starx Research Center, LLC
- |||| Lastacaft (alcaftadine) / J&J, AbbVie
Trial completion: A Study to Evaluate the Efficacy of Lastacaft (clinicaltrials.gov) - Jan 2, 2013
P4, N=157, Completed, Sponsor: Allergan
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| Lastacaft (alcaftadine) / J&J, AbbVie
New P4 trial: A Study to Evaluate the Efficacy of Lastacaft (clinicaltrials.gov) - Nov 22, 2012
P4, N=157, Completed, Sponsor: Allergan
- |||| Lastacaft (alcaftadine) / J&J, AbbVie
Trial completion: A Study to Evaluate the Duration of LASTACAFT (clinicaltrials.gov) - Mar 12, 2012
P4, N=127, Completed, Sponsor: Allergan
Recruiting --> Completed Recruiting --> Completed
- ||||| Lastacaft (alcaftadine) / J&J, AbbVie
New P4 trial: A Study to Evaluate the Duration of LASTACAFT (clinicaltrials.gov) - Nov 9, 2011
P4, N=127, Completed, Sponsor: Allergan